We kick off Wednesday’s highlights with TV and set–top software Mirada (LON:MIRA), which announced it has narrowed losses and boosted sales in its interims.
The company also said the contract roll-out with South American media group Televisa was ahead of schedule.
The specialist reported sales were around £2.25mln in the 6 months to September 30, from £2.1mln in the same period a year ago.
It wasn’t the only firm with big news out today, as Action Hotels (LON:AHCG) told investors it has agreed to a joint venture in Ras Al Khaimah, UAE, where it agreed to acquire a leasehold interest in new hotel back in October last year.
The AIM quoted company said the new partnership with Action Group Holdings, to acquire the building jointly on a freehold basis from Action Real Estate Company, will add greater value to its shareholders.
It was previously envisaged, under the October 2014 deal, that the AIM company would contribute US$4.8mln to refurbish the building and convert the interior of the building into a hotel.
In the mining space, Ortac Resources (LON:OTC) is looking forward to more good news from the Zamsort operation, in Zambia, where a commercial scale demonstration plant has been built.
At Zamsort, which will make copper cement and cobalt hydroxide filter cake, the company has a ten year small mining licence and commissioning is expected in the second quarter of 2016.
Over the past six months Zamsort, where Ortac has a 19.35% interest via a convertible loan, some US$2.6mln has been raised.
Meanwhile, KEFI Minerals (LON:KEFI) is finishing 2015 in a strong position, according to executive chairman Harry Anagnostaras-Adams.
The junior mining company, which released a fourth quarter update today, says it is on track for the first draw-down on its project finance for the Tulu Kapi project, in Ethiopia, by mid-2016. It will see the gold mine start-up in 2017.
In the pharma arena, fast growing drug delivery group Midatech (LON:MTPH, NASDAQ:MTP) has completed the acquisition of Zuplenz, a treatment for the side effects of chemotherapy.
Zuplenz is treatment to prevent nausea and vomiting stemming from radiation-based cancer treatments.
Dr Jim Phillips, chief executive, said: "We are pleased to complete the acquisition of Zuplenz, which adds to our rapidly growing portfolio of marketed oncology products.
In other news, VinaCapital Vietnam (LON:VOF) said for the 12 months to June 30 that its net asset value slipped to US$718.7mln from US$771.4mln the year before, but its NAV per share was higher, up to US$3.27 from US$3.24.
Finally, Sunrise Resources (LON:SRES) reported that Patrick Cheetham, executive chairman, has bought 3mln shares at 0.15p a pop taking his stake in the firm up to around 3.7%.